199 related articles for article (PubMed ID: 22899868)
1. Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs.
Guo W; Liu R; Ono Y; Ma AH; Martinez A; Sanchez E; Wang Y; Huang W; Mazloom A; Li J; Ning J; Maverakis E; Lam KS; Kung HJ
Mol Pharmacol; 2012 Nov; 82(5):938-47. PubMed ID: 22899868
[TBL] [Abstract][Full Text] [Related]
2. Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.
Zhong Y; Dong S; Strattan E; Ren L; Butchar JP; Thornton K; Mishra A; Porcu P; Bradshaw JM; Bisconte A; Owens TD; Verner E; Brameld KA; Funk JO; Hill RJ; Johnson AJ; Dubovsky JA
J Biol Chem; 2015 Mar; 290(10):5960-78. PubMed ID: 25593320
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).
Tang G; Liu L; Wang X; Pan Z
Eur J Med Chem; 2019 Jul; 173():167-183. PubMed ID: 30999237
[TBL] [Abstract][Full Text] [Related]
4. ASK120067 potently suppresses B-cell or T-cell malignancies
Song P; Bai G; Chan S; Zhang T; Tong L; Su Y; Shen Y; Chen Y; Liu Y; Lai M; Ning Y; Tang H; Fang Y; Chen Y; Ding K; Ding J; Xie H
Front Pharmacol; 2022; 13():1071114. PubMed ID: 36588692
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Cx43 Gap Junction Intercellular Communication by Bruton's Tyrosine Kinase and Interleukin-2-Inducible T-Cell Kinase.
Basu I; Li H; Trease AJ; Sorgen PL
Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189407
[TBL] [Abstract][Full Text] [Related]
6. The retinoid derivant ECPIRM selectively exhibited anti-proliferation effects in cutaneous T-Cell lymphoma via ITK-mediated signaling pathway.
Li H; Wang C; Ma P; Zhang M; Yang H; Yuan S; Wei J; Tao L; Qian K; Xu M; Li L
J Dermatol Sci; 2020 Mar; 97(3):208-215. PubMed ID: 32165081
[TBL] [Abstract][Full Text] [Related]
7. A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
Romanchikova N; Strods A; Strazdina J; Strumfs B; Trapencieris P
Anticancer Res; 2016 Nov; 36(11):6133-6140. PubMed ID: 27793942
[TBL] [Abstract][Full Text] [Related]
8. Signaling of the ITK (interleukin 2-inducible T cell kinase)-SYK (spleen tyrosine kinase) fusion kinase is dependent on adapter SLP-76 and on the adapter function of the kinases SYK and ZAP70.
Hussain A; Mohammad DK; Gustafsson MO; Uslu M; Hamasy A; Nore BF; Mohamed AJ; Smith CI
J Biol Chem; 2013 Mar; 288(10):7338-50. PubMed ID: 23293025
[TBL] [Abstract][Full Text] [Related]
9. Itk, a T cell-specific tyrosine kinase, is required for CD2-mediated interleukin-2 promoter activation in the human T cell line Jurkat.
Tanaka N; Abe H; Yagita H; Okumura K; Nakamura M; Sugamura K
Eur J Immunol; 1997 Apr; 27(4):834-41. PubMed ID: 9130632
[TBL] [Abstract][Full Text] [Related]
10. Expression and function of Tec, Itk, and Btk in lymphocytes: evidence for a unique role for Tec.
Tomlinson MG; Kane LP; Su J; Kadlecek TA; Mollenauer MN; Weiss A
Mol Cell Biol; 2004 Mar; 24(6):2455-66. PubMed ID: 14993283
[TBL] [Abstract][Full Text] [Related]
11. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
12. 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).
Winters MP; Robinson DJ; Khine HH; Pullen SS; Woska JR; Raymond EL; Sellati R; Cywin CL; Snow RJ; Kashem MA; Wolak JP; King J; Kaplita PV; Liu LH; Farrell TM; DesJarlais R; Roth GP; Takahashi H; Moriarty KJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5541-4. PubMed ID: 18823779
[TBL] [Abstract][Full Text] [Related]
13. Selective Itk inhibitors block T-cell activation and murine lung inflammation.
Lin TA; McIntyre KW; Das J; Liu C; O'Day KD; Penhallow B; Hung CY; Whitney GS; Shuster DJ; Yang X; Townsend R; Postelnek J; Spergel SH; Lin J; Moquin RV; Furch JA; Kamath AV; Zhang H; Marathe PH; Perez-Villar JJ; Doweyko A; Killar L; Dodd JH; Barrish JC; Wityak J; Kanner SB
Biochemistry; 2004 Aug; 43(34):11056-62. PubMed ID: 15323564
[TBL] [Abstract][Full Text] [Related]
14. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
Ge Y; Yang H; Wang C; Meng Q; Li L; Sun H; Zhen Y; Liu K; Li Y; Ma X
Bioorg Med Chem; 2017 Jan; 25(2):765-772. PubMed ID: 27956037
[TBL] [Abstract][Full Text] [Related]
16. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK).
Wang X; Xue G; Pan Z
Eur J Med Chem; 2020 Feb; 187():111918. PubMed ID: 31830635
[TBL] [Abstract][Full Text] [Related]
19. ITK inhibition for the targeted treatment of CTCL.
Bustos-Villalobos I; Bergstrom JW; Haigh NE; Luna JI; Mitra A; Marusina AI; Merleev AA; Wang EA; Sukhov A; Sultani H; Liu R; Bhardwaj G; Guo W; Kung HJ; Lam KS; Maverakis E
J Dermatol Sci; 2017 Jul; 87(1):88-91. PubMed ID: 28434812
[No Abstract] [Full Text] [Related]
20. A FLIPR-based assay to assess potency and selectivity of inhibitors of the TEC family kinases Btk and Itk.
Douhan J; Miyashiro JS; Zhou X; Cole DC; Wu PW; Collins M; Dunussi-Joannopoulos K
Assay Drug Dev Technol; 2007 Dec; 5(6):751-8. PubMed ID: 18181691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
